Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

VICOM/FCB AWARDED ZOVIRAX DIRECT-TO-CONSUMER AD ACCOUNT from Burroughs Wellcome, the agency announced on Dec. 1. The agency assignment to VICOM's new consumer division, The OTx Group, marks the initial foray into consumer advertising for the prescription antiviral Zovirax (acyclovir). The "primary task" of The OTx Group will be to "develop direct-to-consumer advertising for Zovirax prior to its potential switch to OTC status," New York-based OTx Group explained. Consumer advertising for Zovirax is expected to debut during the first half of 1994, the agency said, and will include print ads. In addition, the OTx Group said it plans to explore the feasibility of television commercials for the genital herpes treatment. The consumer-directed ads will have an educational theme, focusing on proper diagnosis of genital herpes and encouraging visits to the doctor, the agency explained. The ad agency indicated that the stigma attached to the sexually transmitted disease, which can deter patients from seeking treatment from a physician, may be one target of the ad campaign. FDA Antiviral Drug Products Division Medical Officer Heidi Jolson, MD, told physicians attending the October Interscience Conference on Antimicrobial Agents and Chemotherapy that patient education programs will be pivotal to the switch of Zovirax ("The Tan Sheet" Oct. 25, p. 22). Burroughs Wellcome Senior Clinical Research Scientist Gray Davis, MD, reported that the company was already considering different ways of presenting educational materials to consumers. Burroughs Wellcome submitted its application in August for an Rx-to-OTC switch of oral Zovirax for use in the management of recurrent genital herpes. The proposed OTC dosage regimen of two 200 mg tablets twice daily is the same as the current prescription maintenance dose. OTC Zovirax will be marketed by Warner-Wellcome, a joint venture between Warner-Lambert and Burroughs Wellcome announced in July. ("The Tan Sheet" Aug. 2, p. 1). Warner-Lambert indicated that it will be responsible for day-to-day operations and marketing decisions under the agreement. However, Warner-Lambert said that advertising arrangements formalized before the joint venture becomes operational will stand. Warner-Lambert and Burroughs Wellcome predicted at the time of the announcement that Warner-Wellcome would begin operations in January. VICOM announced the formation of The OTx Group in January ("The Tan Sheet" March 8, p. 11). The Zovirax account is the division's second. The division also is directing an educational print campaign for Merck on how to control cholesterol with diet and exercise in several targeted cities. VICOM handles professional advertising for Merck's prescription anticholesterol drugs Mevacor (lovastatin) and Zocor (simvastatin). New York-based Kallir, Philips, Ross, which currently handles professional advertising for Zovirax, also recently added a division focusing on consumer advertising. In February, KPR said it planned to develop its in-house direct-to-consumer capabilities by increasing the staff of the consumer division and moving into consumer marketing of OTCs ("The Tan Sheet" March 1, p. 15).

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts